Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
| Autor: | Sophie Borot, Eve Puzenat, Françoise Cattin, Christophe Borg, Franck Schillo, Marie-Astride Beaudoin, Anne-Sophie Gauthier, François Aubin, Charlée Nardin |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Programmed cell death Lung Neoplasms Skin Neoplasms Anti-Inflammatory Agents Pembrolizumab Antibodies Monoclonal Humanized Methylprednisolone Immune tolerance 03 medical and health sciences Therapeutic approach Antineoplastic Agents Immunological 0302 clinical medicine Immune system Orbital Diseases medicine Humans Pharmacology (medical) Adverse effect Melanoma Aged Inflammation Pharmacology business.industry Prognosis medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Toxicity Cancer research business |
| Zdroj: | Investigational New Drugs. 37:375-377 |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1007/s10637-018-0659-9 |
| Popis: | The recent advent of immune checkpoint inhibitors (ICI), including anti-programmed cell death 1 protein (anti-PD-1) agents has revolutionized the therapeutic approach of metastatic malignancies. Yet, ICI can disrupt immune tolerance resulting in enhanced immune activation in normal tissues with significant toxicity. A dysregulated activation of T-cells directed to normal tissues stands as the main mechanism of immune-related adverse events (irAE). To date, only two cases of immune-related inflammatory orbitopathy related to anti-PD-1 agents have been reported. This rare immune adverse event usually occurred early after ICI initiation. Here, we report the first case of late inflammatory orbitopathy occurring in a melanoma patient treated with pembrolizumab. Consequently, the occurrence of irAE under ICI should be monitored, even late after treatment instauration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink